The Cancer Letter

Inside information on cancer research and drug development

In Brief

UPenn’s Saar Gill receives $300,000 to develop genetically engineered stem cell products to fight gastroesophageal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Saar Gill, of the University of Pennsylvania, has received $300,000 from the DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI), for progress he’s made on a grant for gastroesophageal cancer research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Eric Smith, Andrew Aguirre, Sam Klempner granted additional $300,000 from DeGregorio Family Foundation to study immunotherapy in gastroesophageal cancer

Eric SmithAndrew AguirreSam KlempnerThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, or GEMINI, awarded $300,000 to Eric Smith and Andrew Aguirre, both of Dana-Farber Cancer Institute, and Sam Klempner, of Massachusetts General Hospital, to reward the progress they have made on their grant in a little over a year. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account